Fujifilm brings AI monitoring to CDMO antibody production

Fujifilm's move fits a broader push to bring AI into the manufacturing side of biopharma, not just drug discovery. In its CDMO (contract development and manufacturing organization) business, the company is now monitoring culture medium composition over time so it can analyze how antibody drug culture conditions relate to final production volume and quality. That is a shift from running batches and checking results afterward toward understanding the process as it happens.

Alongside the monitoring work, Fujifilm has built a digital twin of CHO cells — a simulated model of the antibody-producing cells — aimed at predicting production volume. According to Masataka Hasegawa, general manager of the Precision Process Technology Center, and Li Yuanzhong, principal researcher at the Bioscience & Engineering Laboratory, the technology is already being introduced into actual CDMO operations, though the body does not quantify the resulting gains.

The context is the wider entry of AI into manufacturing sites for antibody and cell-based medicines. For a contract manufacturer, the appeal is clear: if culture conditions can be tied more reliably to yield and quality, production planning and consistency may improve. Still, the body presents the capability and its early deployment rather than measured outcomes, so the practical benefit remains to be demonstrated.